--- title: "Evolus | 8-K: FY2026 Q1 Revenue Beats Estimate at USD 73.14 M" type: "News" locale: "en" url: "https://longbridge.com/en/news/285113724.md" datetime: "2026-05-04T20:08:46.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/285113724.md) - [en](https://longbridge.com/en/news/285113724.md) - [zh-HK](https://longbridge.com/zh-HK/news/285113724.md) --- # Evolus | 8-K: FY2026 Q1 Revenue Beats Estimate at USD 73.14 M Revenue: As of FY2026 Q1, the actual value is USD 73.14 M, beating the estimate of USD 72.17 M. EPS: As of FY2026 Q1, the actual value is USD -0.16. EBIT: As of FY2026 Q1, the actual value is USD -11.11 M. #### First Quarter 2026 Financial Results Total net revenues for the first quarter of 2026 were $73.1 million, marking a 7% increase over the first quarter of 2025. This revenue included $66.4 million from global toxin sales and $6.7 million from injectable hyaluronic acid (HA) gels. #### Gross Profit and Margins Gross profit for Q1 2026 was $48.9 million, an increase from $46.7 million in Q1 2025. The gross profit margin stood at 66.9%, while the adjusted gross profit margin was 68.0%, excluding amortization of intangible assets. #### Operating Expenses GAAP operating expenses for the first quarter of 2026 were $55.7 million, an improvement from $61.8 million in the prior year period. Non-GAAP operating expenses were $49.1 million for Q1 2026, compared to $52.9 million in Q1 2025 and $53.0 million in Q4 2025, which included a $4.5 million benefit from a contingent royalty obligation revaluation. #### Operating Profit/Loss GAAP loss from operations significantly improved to - $6.8 million for Q1 2026, from - $15.2 million in Q1 2025. Adjusted EBITDA was $0.6 million for the first quarter of 2026, compared to a loss of - $5.5 million in the first quarter of 2025, marking the second consecutive quarter of positive Adjusted EBITDA. The Adjusted EBITDA margin was 0.8% for Q1 2026, up from -8.1% for Q1 2025. #### Net Loss Net loss for the first quarter of 2026 was - $10.7 million, an improvement from - $18.9 million in the first quarter of 2025. #### Cash Flow and Balance Sheet Net cash used in operating activities was - $9.9 million for the three months ended March 31, 2026, compared to - $15.6 million for the same period in 2025. Net cash used in investing activities was - $1.7 million, and net cash provided by financing activities was $7.6 million for the first quarter of 2026. As of March 31, 2026, Evolus, Inc. held cash and cash equivalents of $49.8 million, down from $53.8 million on December 30, 2025. Total assets were $220.6 million, and total liabilities were $249.4 million as of March 31, 2026. Total stockholders’ equity (deficit) was - $28.8 million, and long-term debt stood at $156.4 million as of March 31, 2026. #### Operational Metrics and Highlights Total purchasing accounts increased by nearly 500 in the first quarter of 2026. Since its launch, over 18,100 customers have purchased from Evolus, Inc., with approximately 3,500 purchasing Evolysse®, which has driven U.S. account penetration above 60%. Customer reorder rates are approximately 71%. Members in the Evolus Rewards™ consumer loyalty program grew by nearly 75,000 during the quarter to approach 1.5 million, representing a 27% increase compared to the first quarter of 2025. Total Evolus Rewards™ redemptions reached an all-time high of over 255,000, with existing patients receiving repeat treatments at approximately 70%. #### Capital Markets Activity Evolus, Inc. terminated a Sales Agreement on May 1, 2026, which had allowed for the offer and sale of up to $50.0 million of its common stock through “at-the-market” offerings; no shares were sold under this agreement prior to its termination. #### Outlook and Guidance Evolus, Inc. reaffirms its full-year 2026 net revenue guidance of $327 million to $337 million, projecting 10% to 13% growth over the prior year. The company expects full-year 2026 non-GAAP operating expenses to range between $210 million and $216 million, anticipating a low- to mid-single digit Adjusted EBITDA margin for the year. For 2028, Evolus, Inc. projects total net revenue between $450 million and $500 million, with Adjusted EBITDA margins expected to be 13% to 15%. ### Related Stocks - [EOLS.US](https://longbridge.com/en/quote/EOLS.US.md) ## Related News & Research - [Evolus (NASDAQ:EOLS) Insider Rui Avelar Sells 3,119 Shares](https://longbridge.com/en/news/280002542.md) - [Evolus, Inc. (NASDAQ:EOLS) Given Consensus Recommendation of "Moderate Buy" by Brokerages](https://longbridge.com/en/news/270033683.md) - [Rui Avelar Sells 2,261 Shares of Evolus (NASDAQ:EOLS) Stock](https://longbridge.com/en/news/271043118.md) - [Evolus (EOLS) Gets a Buy from Stifel Nicolaus](https://longbridge.com/en/news/272410370.md) - [Mizuho Securities Keeps Their Buy Rating on Evolus (EOLS)](https://longbridge.com/en/news/269300159.md)